A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE)
A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE)
placebo controlled adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy
100 项与 Parexel International 相关的临床结果
0 项与 Parexel International 相关的专利(医药)
100 项与 Parexel International 相关的药物交易
100 项与 Parexel International 相关的转化医学